Market research
CODX Co-Diagnostics, Inc. Common Stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 2.88
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US1897632048
- Market cap
- 8M
- P/E ratio
- Not available
- Analyst target
- 4
- Dividend yield
- Not available
- Beta
- 2.88
About
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CODX discussion.
5 years, 4 months ago
Co-Diagnostics, Inc is currently in a long term downtrend where the price is trading 28.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.5.
Co-Diagnostics, Inc's total revenue rose by 24903.4% to $27M since the same quarter in the previous year.
Its net income has increased by 974.7% to $15M since the same quarter in the previous year.
Finally, its free cash flow grew by 1282.3% to $19M since the same quarter in the previous year.
Based on the above factors, Co-Diagnostics, Inc gets an overall score of 4/5.